Homepage
Author:
Shattuck Labs, Inc.
Posted Date:
June 10, 2026
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs, Inc.
June 10, 2026
Shattuck Labs, Inc. Announces Proposed Public Offering
Shattuck Labs, Inc.
June 9, 2026
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Shattuck Labs, Inc.
June 9, 2026
Shattuck Labs Announces Phase 1 Results for SL-325
Shattuck Labs, Inc.
June 8, 2026
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs, Inc.
June 5, 2026
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs, Inc.
May 7, 2026
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Shattuck Labs, Inc.
March 5, 2026
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
Shattuck Labs, Inc.
February 25, 2026
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
Shattuck Labs, Inc.
February 7, 2026
